Please find attached Audited Financail Results for the quarter and year ended March 31, 2026

Emphasis Of MatterResults RestatedPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.5%Reaction day

₹2470.00

prior close

₹2501.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%+4.1% vs market

Pharmaceuticals peers, median of 158sector+0.2%+4.2% vs sector

On the reaction day the stock moved 4.1 pts more than Nifty Midcap 150 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.2

10m

+2.1

15m

+2.2

30m

+2.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.5+0.4+4.1+0.2+4.2

Next day

+2.0+0.5+1.5+0.7+1.3

+0.4+0.6-0.1+0.5-0.1

-0.4+1.4-1.9+1.8-2.2

-2.2+1.9-4.1+1.9-4.2

-1.5+2.3-3.7+2.0-3.5

-6.2-0.5-5.7+1.3-7.5

15d

-3.8-2.9-1.0-0.5-3.3

+3.0+3.1-0.2+4.1-1.1

+4.3+3.2+1.1+8.4-4.1

-3.4+4.5-8.0+9.1-12.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma reported standalone PAT of ₹713.61 Crores for FY26, up 203% from ₹235.16 Crores in FY25. Full year standalone revenue grew 9.6% to ₹10,421.18 Crores. Q4 standalone revenue was ₹2,581.82 Crores with strong EBITDA margin expansion to 35% from 26% in Q3. The Board approved an additional investment of up to ₹500 Crores in wholly-owned subsidiary Mankind Medicare Private Limited, realigned NCD security cover post ₹1,250 Crores redemption, and reappointed Whole-Time Director Satish Kumar Sharma for another 5-year term. Key executive directors voluntarily waived their commission for FY25-26 to strengthen cash position for business expansion. Statutory auditors issued an unmodified opinion but included an Emphasis of Matter regarding ongoing income tax proceedings. Prior year figures were restated for the BSV acquisition.

Likely market impact

Strong profitability growth and margin expansion are positive signals for shareholders. The tax proceedings remain a contingent liability, while the capital deployment in subsidiaries and executive commission waiver suggest management focus on long-term expansion over short-term payouts.